FDA approves Incyte's eczema cream with boxed warnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- US stock futures slip ahead of inflation report
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil gains as stalled US-Iran talks trump supply recovery
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- HPE raises networking revenue outlook, secures $1.2B Vultr order
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Incyte (INCY) Enters Exclusive Supply and Distribution Agreement with Knight Therapeutics for Tafasitamab and Pemigatinib in Latin America
September 23, 2021 7:33 AM EDTKnight Therapeutics Inc. a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sà rl, the Swiss-based affiliate of Incyte (NASDAQ: INCY), for the exclusive rights to distribute tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®) in Latin America. Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply to Knight of tafasitamab and pemigatinib, and Knight will be responsible for seeking... More
Incyte (INCY) Announces FDA Approved Jakafi for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
September 22, 2021 12:39 PM EDTIncyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
GVHD is the leading cause of morbidity and mortality in patients following an allogeneic stem cell transplant, yet there historically have been limited treatment options available beyond first-line systemic therapies, stated Steven Stein, M.D., Chief Medical Officer, Incyte. Incyte is proud to have contributed to the overall scientific understanding of... More
